The leading gene editing company that plummeted 92% may be being given away for free by the market.

Imagine this: someone develops a genetic disease, and a doctor tells him he needs medication for life, costing $470k per year—adding up to potentially over $5 million over a lifetime. Then a company says: we can give you a shot that permanently edits your genes, curing you in one go.

This is not a science-fiction movie. The company is called Intellia Therapeutics, and it has already achieved in vivo CRISPR gene editing in more than 600 patients. $NTLA

Even more unusual: the company’s stock price has crashed from $176 in 2021 to $14.78 today—a 92% drop. Current market cap is $1.75 billion; subtract the $600 million cash on hand, and the market values its two Phase 3 clinical pipeline programs at only $1.15 billion.

Meanwhile, Lilly acquired Verve in 2025 for $1-1.3 billion—a in vivo gene editing company with only Phase 1b data. Intellia has two Phase 3 programs, yet is only worth $1.15 billion?

This is the classic scenario in crisis investing: a great company experiencing a reversible crisis × an extremely low share price misjudged due to emotion × enormous growth potential in terms of market opportunity.

Today, I’ll use my 14-dimensional framework for my “crisis investing research method for growth companies” to thoroughly break down NTLA.

1. What exactly is it doing? The dream factory for curing genetic diseases with one shot

Intellia is the only publicly listed company in the world that has successfully achieved CRISPR gene editing in humans in vivo. Its technical principle is very simple: by intravenous injection, deliver lipid nanoparticles loaded with CRISPR tools into your body to precisely edit the disease-causing genes. One injection—permanently effective.

Two core products, two hundred-billion-dollar-level markets

Nex-z (ATTR amyloidosis): One injection permanently lowers TTR protein by 90%+; stable over a 36-month follow-up with no rebound. 47% of patients see an improvement of at least 1 grade in cardiac function. Compare this: the current lifetime medication cost for ATTR patients is $270k–$480k per year, or $2.7m–$4.8m over 10 years.

Lonvo-z (HAE hereditary angioedema): Even more impressive—among 32 patients, 97% achieved complete attack freedom after a single injection, with follow-up over 32 months. Monthly attack rate drops by 96%. Previously, these HAE patients had to spend $550k–$680k annually on preventive medication—now one shot solves it.

Let’s do a quick calculation: if HAE patients use traditional drugs for 20 years, the cost exceeds $13.6 million. If gene editing is priced at $1 million one time, it saves over $12.6 million. This isn’t only a blessing for patients—it’s also the core logic that payers and healthcare insurance systems can accept high-priced gene editing.

2. Why is it so cheap? Four-crisis recap

Understanding why it fell from $176 to $14 is the premise for buying. This isn’t a one-time plunge, but four overlapping crises:

Crisis #1: A sector-wide biotech crash (2021–2024): With rising interest rates + retreat of capital, the entire gene editing sector plunged 70–90% from its peak. CRSP, BEAM, and EDIT all had no escape.

Crisis #2: Patient death incident (Q4 2025): In the MAGNITUDE trial, an ATTR-CM patient died, triggering a sharp one-day stock plunge. Although the investigation results show the cause of death was unrelated to nex-z (the patient belonged to late-stage, high-risk ATTR-CM), market panic had already formed.

Crisis #3: FDA clinical hold (December 2025): The FDA issued a clinical hold on MAGNITUDE and MAGNITUDE-2, requiring submission of additional safety data. The stock plunged again to a historical low of $6.73 (intraday).

Crisis #4: Layoffs + pipeline cuts (January 2025): 42% of employees were laid off, and multiple pipeline projects such as NTLA-3001 were cut. The market’s interpretation was: “It can’t survive much longer.”

But—pay attention to this “but”—each of these four crises has already shown signals of positive reversal:

✅ Sector rebound: In 2026 Q1, the gene editing sector rebounded overall, and Citizens raised its target price to $28.

✅ Clarification on the death incident: After FDA evaluation, it was confirmed that the cause of death was unrelated to the treatment.

✅ Clinical hold lifted: On March 2, 2026, the FDA fully lifted the clinical hold, and the MAGNITUDE trial resumed enrollment. The stock rebounded nearly 4.8% that day.

✅ Layoffs = focus: Cutting non-core pipeline programs and concentrating all resources on the two most valuable Phase 3 products is a rational strategic contraction.

3. Is it legit? Nobel Prize founder + pharma veteran

CEO John Leonard: Former AbbVie Chief Scientific Officer; personally developed Humira, the highest-selling drug in the global history. He joined Intellia in 2014 as its first employee recruited, and became CEO in 2018. His wife has multiple sclerosis—this is the personal driving force behind his decision to devote himself to new drug development.

Founding team: Jennifer Doudna (2020 Nobel Prize in Chemistry, co-inventor of CRISPR), Derrick Rossi (co-founder of Moderna), Rodolphe Barrangou (a member of the U.S. National Inventors Hall of Fame), and other 7 top scientists—founded the company together in 2014.

The most important insider signal: Director Fred Cohen bought 150,000 shares on January 5, 2026 at $9.35/share in the public market, investing about $1.4 million. This is a rare large-scale insider open-market purchase.

4. Competitive landscape: in vivo vs ex vivo, dimensionality-reduction attack

Many people compare Casgevy (a product by CRISPR Therapeutics, the first approved CRISPR drug globally) with Intellia—but that’s a mistake. They are two entirely different “species”:

Casgevy (ex vivo): Needs to extract patients’ stem cells → edit outside the body → myeloablative chemotherapy → reinfuse. The process is complex, high-risk, and not repeatable. In 2025, it completed fewer than 100 administrations.

Intellia (in vivo): Simple intravenous injection → directly edits the gene in the body. No hospitalization, no chemotherapy, and repeatable dosing. In the MAGNITUDE single study alone, it has dosed 650+ patients.

That’s why Lilly spent $1.3 billion to acquire Verve (also in vivo gene editing, but only Phase 1b data), while Intellia has two Phase 3 programs yet is only valued at $1.75 billion.

5. Cross-validation with ten valuation methods (core conclusion)

This is the part where I spend the most time on valuation research. Go straight to the conclusion:

Valuation method Valuation result Corresponding share price

① rNPV (probability-weighted net present value) ~$3.77 billion ~$32/share

② Comparable transaction (Verve acquisition as reference) $2–3 billion $17–25/share

③ Comparable companies (CRSP/BEAM as reference) $1.5–$1.6 billion ~$13–$14/share

④ DCF base scenario $25–35/share $25–35/share

⑤ Book value (hard floor) $671 million $5.69/share

⑥ Market cap / cash ratio Pipeline only priced at $1.15 billion Significantly undervalued

⑦ Market cap per pipeline $875 million per pipeline < Verve’s $1–1.3 billion per pipeline

⑧ Replacement cost method $3–5 billion $25–42/share

⑨ Analyst consensus target price Median $19–22 +30–50% upside

⑩ Historical valuation range ATH $176 / 52-week low $6.73 Current at 92% percentile of ATH

Overall conclusion: NTLA’s reasonable valuation range is $20–35/share (base case), implying 35–137% upside from the current $14.78.

Note: The analyst target price range is extremely dispersed ($5–$106). This reflects NTLA’s core contradiction: if HAELO data succeeds, this is a $3–$5 billion company; if it fails, it may be worth only the cash on its balance sheet. Market disagreement itself is an opportunity.

6. Short interest ratio of 33%: historic potential for a short squeeze cover

NTLA’s short interest is 33% of the float (about 39 million shares), and the days to cover is 7.7–10.8 days. This is an extremely high short level.

If HAELO data is positive, considering that the days to cover is over 7 days, the short covering could potentially trigger an extremely violent short-squeeze rally. Short interest has fallen from a peak of 44.31 million shares to 39.44 million shares, showing that some shorts are beginning to cover.

Institutional ownership is about 88.6% (315 institutions). The top three holders are ARK Investment (Cathie Wood), Vanguard, and BlackRock. Regeneron is also among the top ten institutional shareholders.

7. The most critical catalysts: life-or-death decisions within 2–3 months

This is the core of the entire investment thesis:

Catalyst Time Impact

**HAELO Phase 3 unblinding Mid-2026 **Decisive event! Success = BLA submission; failure = major negative

Lonvo-z BLA submission H2 2026 Starts the FDA review process

Q1 2026 financial report April 30, 2026 Cash update, pipeline progress

Lonvo-z U.S. listing H1 2027 First product revenue

8. Where are the risks? Three unavoidable pitfalls

① Tight cash runway: $605 million in cash, quarterly burn of about $64 million, runway of about 18–22 months. If HAELO data is delayed or fails, the company must raise funds before 2027, which means dilution. The good news is that the company has already reserved $1.04 billion in ATM financing capacity.

② Binary clinical outcomes: HAELO is a binary event—if successful, the stock could potentially double; if it fails, it could fall to a $3–$5 cash value. There is no middle ground.

③ Securities litigation: A securities class action lawsuit was filed in February 2025, alleging that the company made misleading statements about the NTLA-3001 program. There is currently no finding of substantive fraud evidence, but continuous monitoring is required.

9. Conclusion: Buy cautiously, build positions in batches

Three back-to-back questions for position-building:

Are you willing to become a shareholder of this company? Yes. A one-shot cure for a genetic disease is one of the most transformative innovations in medical history.

Can you sleep well after buying? It depends on your position size. I suggest keeping it at 2–5% of the total portfolio.

Is there a 10x upside in 5 years? The probability of 10x is about 5–10%, but the probability of 3–5x (around $45–$75) is about 25–35%. In high-risk biotech investing, this is still an attractive asymmetric return.

Recommended staged position-building strategy:

First batch (30% position size): Build a base position at the current price.

Second batch (40% position size): Add after HAELO data is positive.

Third batch (30% position size): Complete after BLA submission is confirmed.

Stop-loss line: If HAELO data fails to meet expectations, immediately apply the stop-loss and exit.

The core logic for investing in NTLA can be summarized in one sentence:

Do you believe that a one-shot cure for genetic diseases will become a reality, and that Intellia is the best vehicle to realize this vision? Given the current price, the market has delivered an extremely pessimistic answer. If the market is wrong, the returns will be astonishing.

⚠️: This article is for personal research sharing only and does not constitute any investment advice!